Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co. (NYSE:LLY), disclosed the sale of shares worth approximately $183.6 million, according to recent filings. The transactions, which ...

According to Benzinga Pro, Eli Lilly's peer group average for short interest as a percentage of float is 4.12%, which means ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, diabetes, immunology, neuroscience, and other therapies. The company is one ...

Most analysts love Eli Lilly and, which has an average rating of buy. But there's reason to believe the stock may be overvalued at today's price of $785.41 per share. Let's look at the fundamentals ...

If any pharmaceutical producer is going to exploit the full potential of such medications, it's the well-capitalized Eli Lilly. I would even consider it to be a leading healthcare stock ...

Investing.com -- Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from competitor Novo Nordisk (NYSE:NVO) regarding their new weight ...

Warren Buffett Sends Wall Street a Grim $127 Billion Warning: History Says the Stock Market Will Do This in 2025. Warren Buffett Sold Over $134 Billion Worth of Stock in 2024, But His Most Recent ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...